Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer a Single Arm Multi-center Open-label Study

Next Previous
Trial Profile

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer a Single Arm Multi-center Open-label Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2019

At a glance

  • Drugs Icotinib (Primary)
  • Indications Lung cancer
  • Focus Therapeutic Use
  • Acronyms CHALLENGE
  • Sponsors Betta Pharmaceuticals Co Ltd

    • Most Recent Events

    • 21 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top